What healthcare investment bankers actually do

One coverage group, six businesses

Say "healthcare coverage" to someone outside the group and they picture one thing: hospitals, maybe, or drug companies. Say it to someone who has actually staffed on a healthcare deal and they'll ask you which sub-sector you mean, because the honest answer is that healthcare investment banking is six or seven different businesses wearing one coverage badge. A biopharma company burning cash toward a clinical trial readout, a medical device maker selling capital equipment to hospitals, a life science tools company selling lab instruments to biopharma itself, a hospital system billing insurers for patient care, a health insurer collecting premiums, and a software company selling scheduling tools to all of the above, all sit inside the same vertical at most banks.

That range is the first thing to understand about the job, because it changes what "healthcare banker" actually means day to day. A biopharma-focused analyst spends the bulk of their time thinking about clinical catalysts, cash runway, and licensing economics. A services-focused analyst spends their time on more conventional cash-flow modeling, payor contracts, and add-on acquisitions for a private equity-backed platform. Both people have "healthcare" on their business card. The full landscape of how those sub-sectors differ in business model and valuation is mapped out in the healthcare sub-sector map, and it's worth reading before you walk into any healthcare-specific interview, because interviewers assume you already know the group isn't one thing.

The deal types you'll actually work on

Healthcare coverage runs the full product menu, but the mix looks different than in a more homogeneous sector.

Notice how different the "typical deal" looks depending on which sub-sector you're staffed on. A biopharma analyst might go a full year without touching a leveraged buyout model. A services analyst might go a full year without ever building a risk-adjusted valuation. The mechanics of licensing deals, and why they're structured the way they are instead of as outright acquisitions, are covered in healthcare deal structures: licensing and milestones. The capital markets side of biopharma, which is unusually heavy relative to other sectors, is covered in biotech IPOs and follow-on offerings.

A day in the life, across sub-sectors

The generic "day in the life" answer that works for a generalist banking interview, building models, updating pitch books, sitting in on calls, applies here too, but the content of that work diverges quickly by sub-sector.

On a biopharma deal, a meaningful chunk of analyst time goes into building and updating a risk-adjusted valuation of the company's pipeline, which means tracking every clinical trial the company has running, its expected readout date, and how the market is pricing the probability of success implied by the stock. Diligence calls involve outside medical or regulatory consultants as often as they involve the company's own CFO, because the deal team needs an independent read on the science before it can trust management's own projections. News flow matters enormously: a single trial result, positive or negative, can move a biopharma company's value by a large multiple of its size overnight, so tracking a coverage list's clinical calendar is a constant background task.

On a medtech or life science tools deal, the work looks more like a traditional industrials process: building out a three-statement model, benchmarking margins and growth against a comparable set of public companies, and digging into the durability of a customer base and a product cycle. The distinctive piece is understanding reimbursement exposure, since a device's growth can depend on whether a payor's coverage policy changes, a topic covered fully in medtech and life science tools economics.

On a provider or payor deal, the work leans hardest on unit economics: patient volumes, payor mix, and reimbursement rates by contract, often for a business with dozens or hundreds of individual locations that each need to be understood at some level of granularity for a roll-up thesis to hold up. That whole framework, including why interviewers push so hard on separating volume growth from rate growth, is in healthcare services: providers and payors.

The vocabulary you need, without a science degree

The single most common misconception among candidates outside the group is that healthcare banking requires a scientific or clinical background. It doesn't, and interviewers are generally more interested in whether you can learn the sector's vocabulary quickly than in whether you already know it from a prior degree. What you do need is fluency in a specific, learnable set of terms and mechanisms:

Clinical trial phases: Phase 1 tests safety in a small group, Phase 2 tests early efficacy and dose in a larger group, and Phase 3 tests efficacy against a control at the scale needed to support regulatory approval. A Phase 3 readout is a far bigger valuation event than a Phase 1 readout because it's the last major hurdle before an approval decision.

Regulatory approval: in the United States, a drug needs approval from the Food and Drug Administration before it can be marketed, and a device needs a comparable clearance or approval pathway depending on its risk classification. Approval timing is one of the biggest uncertainties in any biopharma valuation.

Patent exclusivity and the patent cliff: a drug is protected from generic competition for a defined period, and losing that protection triggers a steep revenue decline as lower-cost competitors enter. The mechanics, and why they're the single biggest driver of large pharma M&A, are in pharma business models, pipelines, and patent cliffs.

Reimbursement: the payment a provider or device company receives from an insurer or government payor, as distinct from a price the seller sets freely. Almost every services and payor question comes back to this concept in some form.

Small molecules and biologics: a small molecule is a chemically synthesized drug, generally simple enough to be manufactured consistently by different companies once its patent expires, which is why small-molecule drugs face generic competition at the patent cliff. A biologic is manufactured from living cells and is far harder to replicate exactly, so instead of a generic it faces a biosimilar, a highly similar but not identical version that goes through its own, separate regulatory pathway. Knowing the distinction matters because it changes how sharp a company's patent cliff is likely to be.

None of this requires a chemistry background. It requires the same thing every other coverage group requires: reading the news, following a coverage list, and being able to explain a mechanism clearly when asked.

Who you actually work with

The counterparties change as much as the deal types do, and that's worth understanding before you claim in an interview that you want the group. On the biopharma side, you're most often dealing with a small management team, sometimes just a CEO and a CFO, at a company that may have fewer than a hundred employees, most of them scientists rather than businesspeople. Those conversations tend to be intense and detail-heavy on the science, because the entire company's value rides on a handful of trial outcomes the management team understands better than anyone in the room. On the large pharma side, you're dealing with a corporate development function that runs its own systematic process for scouting acquisition and licensing targets across the industry, and that team thinks in years, not quarters, because a pipeline decision made today won't show up in revenue for the better part of a decade.

On the services and provider side, the counterparties are often first-time sellers: a physician who built a practice over twenty years, or a family that has run a regional home health business for two generations, weighing a sale for the first time in their lives. That's a very different relationship than dealing with a repeat corporate development team, and it changes how you run the process, since a first-time seller needs more explanation of basic mechanics that a professional acquirer would already know. Financial sponsors show up constantly as buyers in this part of the sector, since physician-practice and home-health platforms are a common leveraged buyout target, which means healthcare coverage bankers work alongside a financial sponsors team on a large share of services deals.

How this differs from other coverage groups

The clearest way to see the difference is to compare it to a coverage group with one dominant business model. A consumer and retail banker learns one valuation grammar, EBITDA multiples adjusted for growth and brand strength, and applies it across a wide range of similar companies. A healthcare banker has to hold several grammars at once and know when each one applies: risk-adjusted valuation for pre-revenue biopharma, conventional multiples for profitable medtech, volume-and-rate decomposition for services and payors. That range is the reason the sector recruits candidates who like breadth, and it's the reason a canned "I want healthcare" answer falls apart the moment an interviewer asks a specific follow-up. The full framework for answering the fit question well is in how to answer why healthcare.

It's also a group with an unusually direct pipeline into specialized buy-side roles after banking, because the sector knowledge is scarce and portable. That path is covered in full in healthcare exit opportunities.

Practice question

Walk me through what a typical week looks like for a healthcare investment banking analyst.

It depends heavily on which part of the healthcare group I'm staffed in, and I'd want to name that upfront because the sub-sectors genuinely feel like different jobs. If I'm on a biopharma-focused team, a lot of my week goes into tracking the coverage list's clinical trial calendar, since a single trial readout can move a company's value dramatically, and into building or updating risk-adjusted valuations that weight future cash flows by the probability a drug candidate actually reaches approval. If I'm on a services or provider-focused team instead, my week looks more like traditional M&A and LBO work: building three-statement models, benchmarking unit economics like patient volume and reimbursement rate across a set of comparable businesses, and supporting diligence on an add-on acquisition for a platform company. Across both, I'd be doing the standard analyst work too, building comps, updating pitch books, and sitting in on management and diligence calls. What ties it together is that healthcare requires switching between very different valuation frameworks depending on the sub-sector, which is different from a coverage group where one method applies across the whole client base.

What the interviewer is listening for: whether you understand that "healthcare banking" isn't one job, since a candidate who describes only one sub-sector's work as if it were universal hasn't done real research on the group. They're also checking that you can name specific, correct mechanics (clinical calendars, risk-adjusted valuation, volume and rate) rather than generic banking-analyst filler that could apply to any coverage group.